| Sep 26 |
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
|
| Sep 12 |
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
|
| Sep 3 |
VYNE Therapeutics to Participate in September Investor Conferences
|
| Aug 16 |
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 15 |
VYNE Therapeutics GAAP EPS of -$0.22 beats by $0.01, revenue of $0.2M beats by $0.09M
|
| Aug 14 |
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 16 |
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
|
| Jul 11 |
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
|
| Jul 9 |
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
|
| Jun 26 |
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
|
